This Article Full Text Full Text (PDF) All Versions of this Article: 114/18/1962    most recent CIRCULATIONAHA.106.664672v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mullen, M. J. Articles by Jux, C. Search for Related Content PubMed PubMed Citation Articles by Mullen, M. J. Articles by Jux, C. Related Collections Other Stroke Treatment - Surgical Transient Ischemic Attacks Catheter-based coronary and valvular interventions: other Pediatric and congenital heart disease, including cardiovascular surgery

(Circulation. 2006;114:1962-1967.)
© 2006 American Heart Association, Inc.

Interventional Cardiology

BioSTAR Evaluation STudy (BEST)

A Prospective, Multicenter, Phase I Clinical Trial to Evaluate the Feasibility, Efficacy, and Safety of the BioSTAR Bioabsorbable Septal Repair Implant for the Closure of Atrial-Level Shunts

Michael J. Mullen, MB, BS, MRCP, MD; David Hildick-Smith, MD, MRCP; Joseph V. De Giovanni, MD, FRCP, FRCPCH, MOM; Christopher Duke, MB, ChB, MA, MRCP; W. Stewart Hillis, MB, ChB, FRCP, FRCS; W. Lindsay Morrison, MD, FRCP; Christian Jux, MD

From Royal Brompton Hospital (M.J.M.), London, United Kingdom; Royal Sussex County Hospital (D.H.-S.), Brighton, United Kingdom; University Hospital (J.V.D.G.), Birmingham, United Kingdom; Glenfield Hospital (C.D.), Leicester, United Kingdom; Western Infirmary (W.S.H.), Glasgow, United Kingdom; Cardiothoracic Centre (W.L.M.), Liverpool, United Kingdom; and Georg-August University (C.J.), Goettingen, Germany.

Correspondence to Dr Michael J. Mullen, Consultant Cardiologist, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, England. E-mail m.mullen{at}rbht.nhs.uk

Received September 16, 2006; revision received September 30, 2006; accepted October 3, 2006.

Background— The use of permanent synthetic implants to close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations, including late complications and the limiting of transeptal access to the left heart should it be required for the later treatment of acquired heart disease. BioSTAR is a novel, bioabsorbable, atrial septal repair implant. This phase I pilot study evaluates the feasibility, safety, and effectiveness of BioSTAR for the first time in humans.

Methods and Results— We conducted a prospective, open-label, multicenter clinical study in 58 patients aged 28 to 68 years who had a clinically significant ASD or PFO. Percutaneous shunt closure was undertaken with the BioSTAR septal repair implant. Successful device implantation was achieved in 57 (98%) of 58 patients. Closure at 30 days and 6 months, assessed by contrast transthoracic echocardiography, was 48 (92%) of 52 and 54 (96%) of 56, respectively. There was no evidence of a clinically significant response to the device. Transient atrial arrhythmia occurred in 5 patients after implantation. No major safety issues were observed.

Conclusions— This study demonstrates the feasibility, safety, and effectiveness of BioSTAR for the closure of ASD and PFO in humans with a high rate of early and complete shunt closure. BioSTAR is a novel septal repair implant designed to provide biological closure of atrial-level defects using the patient’s natural healing response. Because 90% to 95% of the implant is absorbed and replaced with healthy native tissue, future access to the left atrium may be achieved.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				T. P. Graham Jr The Year in Congenital Heart Disease J. Am. Coll. Cardiol., July 24, 2007; 50(4): 368 - 377. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]